Advertisement
AXON vs XERS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and XERS is a Buy.
AXON in upward trend: price may jump up because it broke its lower Bollinger Band on November 06, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 30 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
Momentum Indicator for XERS turns positive, indicating new upward trend
XERS saw its Momentum Indicator move above the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 72 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XERS just turned positive on November 05, 2026. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +21.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in 223 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 191 of 232 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
XERS broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XERS's P/B Ratio (-284.700) is very low in comparison to the industry average of (6.379). XERS has a moderately low P/E Ratio (-152.000) as compared to the industry average of (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
AXON | XERS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 83 | 7 | |
SMR RATING 1..100 | 81 | 100 | |
PRICE GROWTH RATING 1..100 | 66 | 34 | |
P/E GROWTH RATING 1..100 | 80 | 99 | |
SEASONALITY SCORE 1..100 | 30 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XERS's Valuation (1) in the Pharmaceuticals Major industry is significantly better than the same rating for AXON (90) in the Biotechnology industry. This means that XERS’s stock grew significantly faster than AXON’s over the last 12 months.
XERS's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for AXON (83) in the Biotechnology industry. This means that XERS’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to XERS’s over the last 12 months.
XERS's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as AXON (66) in the Biotechnology industry. This means that XERS’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (80) in the Biotechnology industry is in the same range as XERS (99) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to XERS’s over the last 12 months.
| AXON | XERS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 73% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 87% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 86% |
| Advances ODDS (%) | 16 days ago 74% | 3 days ago 86% |
| Declines ODDS (%) | 2 days ago 70% | 10 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while XERS’s FA Score has 2 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- XERS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while XERS’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 5 bearish.
- XERS’s TA Score: 4 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -27.37% price change this week, while XERS (@Pharmaceuticals: Generic) price change was +52.95% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +5.10%. For the same industry, the average monthly price growth was -0.96%, and the average quarterly price growth was -12.76%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
AXON is expected to report earnings on Mar 02, 2027.
XERS is expected to report earnings on Mar 10, 2027.
Industries' Descriptions
@Aerospace & Defense (+5.10% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
XERS and
Correlation & Price change
A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.
| Ticker / NAME | Correlation To XERS | 1D Price Change % | ||
|---|---|---|---|---|
| XERS | 100% | -0.19% | ||
| MIRM - XERS | 45% Loosely correlated | +1.33% | ||
| KROS - XERS | 38% Loosely correlated | +1.74% | ||
| AXON - XERS | 37% Loosely correlated | -0.21% | ||
| REPL - XERS | 36% Loosely correlated | +4.58% | ||
| BNTC - XERS | 36% Loosely correlated | -5.98% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GLL | 26.46 | 1.39 | +5.54% |
| ProShares UltraShort Gold (GLL) | |||
| SIFI | 42.38 | N/A | N/A |
| Harbor Ares Systematic Multi-Sector Income ETF (SIFI) | |||
| JMHI | 48.63 | -0.11 | -0.23% |
| JPMorgan High Yield Municipal ETF (JMHI) | |||
| FETH | 20.48 | -0.69 | -3.26% |
| Fidelity Ethereum Fund ETF (FETH) | |||
| DZZ | 1.51 | -0.06 | -3.82% |
| Deutsche Bank Ag London Gold Double Short Exchange Traded (Nts) (DZZ) | |||